Buy CJC-1295 With DAC Research Peptide

What is CJC-1295 With DAC?

CJC-1295 with DAC is a GHRH version engineered to bind to a blood protein (albumin), which stretches its active life from minutes to about six days. It is used in animal and laboratory research to study the effects of long-lasting growth-hormone signaling.

• A GHRH version that binds albumin to stay active far longer in the body
• Active for around 6 days versus about 30 minutes for unmodified GHRH in studies
• Used in research to study prolonged growth hormone and IGF-1 signaling
• A tool for studying sustained growth-hormone-axis activity in animal models

For research use only. Not approved for human therapeutic use.

CJC-1295 With DAC (Drug Affinity Complex) is a synthetic 30-amino acid analogue of growth hormone-releasing hormone (GHRH). With a molecular weight of 3647.28 g/mol, CJC-1295 DAC (CAS 446262-90-4) features a maleimidopropionyl group conjugated to a C-terminal lysine residue, designed to facilitate bioconjugation with serum albumin. Produced via solid-phase peptide synthesis, CJC-1295 DAC acts at the GHRH receptor (GHRH-R).

CJC-1295 With DAC is investigated in preclinical endocrinology for its extended pharmacokinetic profile relative to unmodified GHRH analogues. The DAC bioconjugation strategy represents a distinct approach to prolonging peptide half-life through albumin binding rather than sequence modification alone, and has been a subject of particular research interest. In vitro studies in rat anterior pituitary somatotroph preparations have examined GHRH-R binding characteristics and downstream cAMP-mediated signalling, characterising the receptor binding kinetics that underpin CJC-1295 DAC’s agonist activity at GHRH-R [1]. Published pharmacokinetic studies in rodent models have investigated sustained receptor engagement and prolonged circulating peptide concentrations following a single administration, with researchers examining albumin-peptide dissociation kinetics and their implications for extended receptor occupancy duration [2].

CJC-1295 With DAC is produced to research-grade standards and independently verified by third-party HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Seifert H, Perrin M, Rivier J, Vale W. Binding sites for growth hormone releasing factor on rat anterior pituitary cells. Nature. 1985 Feb;313(6002):487–9.doi:10.1038/313487a02Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005 Jul;146(7):3052–8. .PubMed PMID: 15817669

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →

CJC-1295 With DAC (Drug Affinity Complex) is a synthetic 30-amino acid analogue of growth hormone-releasing hormone (GHRH). With a molecular weight of 3647.28 g/mol, CJC-1295 DAC (CAS 446262-90-4) features a maleimidopropionyl group conjugated to a C-terminal lysine residue, designed to facilitate bioconjugation with serum albumin. Produced via solid-phase peptide synthesis, CJC-1295 DAC acts at the GHRH receptor (GHRH-R).

CJC-1295 With DAC is investigated in preclinical endocrinology for its extended pharmacokinetic profile relative to unmodified GHRH analogues. The DAC bioconjugation strategy represents a distinct approach to prolonging peptide half-life through albumin binding rather than sequence modification alone, and has been a subject of particular research interest. In vitro studies in rat anterior pituitary somatotroph preparations have examined GHRH-R binding characteristics and downstream cAMP-mediated signalling, characterising the receptor binding kinetics that underpin CJC-1295 DAC’s agonist activity at GHRH-R [1]. Published pharmacokinetic studies in rodent models have investigated sustained receptor engagement and prolonged circulating peptide concentrations following a single administration, with researchers examining albumin-peptide dissociation kinetics and their implications for extended receptor occupancy duration [2].

CJC-1295 With DAC is produced to research-grade standards and independently verified by third-party HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Seifert H, Perrin M, Rivier J, Vale W. Binding sites for growth hormone releasing factor on rat anterior pituitary cells. Nature. 1985 Feb;313(6002):487–9.doi:10.1038/313487a02Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005 Jul;146(7):3052–8. .PubMed PMID: 15817669

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →CAS Number863288-34-0Molecular Weight3,647.28 g/molPurity≥98%Physical FormLyophilised PowderManufacturingManufactured in an ISO9001 Certified LaboratoryTestingHPLC + MS-UPLCSKURSC-CJC1295WIT-6091

Lyophilised powder: store at -20 °C or below, away from light and moisture. Once reconstituted in an appropriate laboratory diluent (e.g. sterile water, PBS, or assay buffer), store at 2–8 °C and use within the validated period for your protocol. Do not refreeze.

CJC-1295 With DAC (Drug Affinity Complex) is a synthetic 30-amino acid analogue of growth hormone-releasing hormone (GHRH). With a molecular weight of 3647.28 g/mol, CJC-1295 DAC (CAS 446262-90-4) features a maleimidopropionyl group conjugated to a C-terminal lysine residue, designed to facilitate bioconjugation with serum albumin. Produced via solid-phase peptide synthesis, CJC-1295 DAC acts at the GHRH receptor (GHRH-R).

CJC-1295 With DAC is investigated in preclinical endocrinology for its extended pharmacokinetic profile relative to unmodified GHRH analogues. The DAC bioconjugation strategy represents a distinct approach to prolonging peptide half-life through albumin binding rather than sequence modification alone, and has been a subject of particular research interest. In vitro studies in rat anterior pituitary somatotroph preparations have examined GHRH-R binding characteristics and downstream cAMP-mediated signalling, characterising the receptor binding kinetics that underpin CJC-1295 DAC’s agonist activity at GHRH-R [1]. Published pharmacokinetic studies in rodent models have investigated sustained receptor engagement and prolonged circulating peptide concentrations following a single administration, with researchers examining albumin-peptide dissociation kinetics and their implications for extended receptor occupancy duration [2].

CJC-1295 With DAC is produced to research-grade standards and independently verified by third-party HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Seifert H, Perrin M, Rivier J, Vale W. Binding sites for growth hormone releasing factor on rat anterior pituitary cells. Nature. 1985 Feb;313(6002):487–9.doi:10.1038/313487a02Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005 Jul;146(7):3052–8. .PubMed PMID: 15817669

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →CAS Number863288-34-0Molecular Weight3,647.28 g/molPurity≥98%Physical FormLyophilised PowderManufacturingManufactured in an ISO9001 Certified LaboratoryTestingHPLC + MS-UPLCSKURSC-CJC1295WIT-6091

Lyophilised powder: store at -20 °C or below, away from light and moisture. Once reconstituted in an appropriate laboratory diluent (e.g. sterile water, PBS, or assay buffer), store at 2–8 °C and use within the validated period for your protocol. Do not refreeze.